Catalent Inc Overview
Company Headquarters: New Jersey, United States
Founded: 2007
Workforce: ~ 19,000
Company Working: Catalent Inc., offer distinct development and manufacturing solutions for pharmaceuticals, protein-based biologics, cell and gene therapies, vaccines, and consumer health products, all while adhering to exacting quality and operating standards. The companies cut-edge protein, plasmid, and respiratory delivery technologies, as well as its injectable, oral, and respiratory. The company typically operates in four business divisions: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services.
Under its biologics segment, offers formulation, development, and manufacturing services for parenteral dose forms, such as vials, prefilled syringes, and cartridges, as well as analytical development and testing for large molecules, viral vaccines, cell therapy, and viral-based gene therapies. The company has vast experience in commercial manufacturing, scale-up, and development. A wide range of creative small and mid-tier biopharmaceutical customers, as well as Moderna, Johnson & Johnson, BMS, AstraZeneca, and Sarepta Therapeutics, are representative clients of biologics.
Moreover, its softgel and oral technologies the company offer formulation, development, and manufacturing services for soft capsules, or "softgels," as well as large-scale production of "softgels," oral solid dose forms, for the pharmaceutical and consumer health markets, through its Softgel and Oral Technologies segment. The company also provide formulation, development, and manufacture of various experience dose forms for the delivery of dietary supplements and other nutraceuticals after fiscal 2022 acquisition of Bettera Wellness.
Furthermore, under its oral and specialty delivery the company offers complete downstream clinical development and commercial supply solutions along with advanced analytical and formulation development and production across a variety of technologies. The technologies cover a wide range of oral, respiratory, and inhaled dose forms, such as nasal delivery systems, metered dose inhalers, dry powder inhalers, and its own fast-dissolving Zydis tablets (as well as numerous bioavailability enhancement technologies for both immediate and controlled-release tablets and capsules).
